Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neurocrine Bioscienc
(NQ:
NBIX
)
140.71
+0.88 (+0.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
Next >
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Via
Investor's Business Daily
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
February 28, 2024
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.
February 28, 2024
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
Via
Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.
Via
Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
February 23, 2024
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
Via
Investor's Business Daily
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
February 16, 2024
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.
Via
Investor's Business Daily
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
February 08, 2024
Via
Benzinga
Earnings Scheduled For February 7, 2024
February 07, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.
Via
Benzinga
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
February 07, 2024
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
February 15, 2024
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday.
Via
Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
February 13, 2024
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
February 12, 2024
Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts.
Via
Benzinga
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
February 09, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
Via
Investor's Business Daily
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
February 08, 2024
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Earnings Outlook For Neurocrine Biosciences
February 06, 2024
Via
Benzinga
NASDAQ:NBIX is not too expensive for the growth it is showing.
February 06, 2024
While growth is established for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), the stock's valuation remains reasonable.
Via
Chartmill
Unveiling 13 Analyst Insights On Neurocrine Biosciences
January 23, 2024
Via
Benzinga
NASDAQ:NBIX, a growth stock which is not overvalued.
January 15, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank.
Via
Chartmill
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
January 12, 2024
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase.
Via
Chartmill
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
January 02, 2024
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.
Via
InvestorPlace
Amgen Stock Sees Relative Strength Rating Improve To 74
December 29, 2023
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.
Via
Investor's Business Daily
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
December 28, 2023
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.
Via
Investor's Business Daily
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
December 28, 2023
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81.
Via
Investor's Business Daily
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
December 26, 2023
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.
Via
Investor's Business Daily
3 Stocks at the Forefront of Medical Innovation
December 25, 2023
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.
Via
InvestorPlace
NASDAQ:NBIX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
December 22, 2023
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout.
Via
Chartmill
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
December 22, 2023
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable.
Via
Chartmill
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
December 21, 2023
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.
Via
Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy in December
December 15, 2023
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.